Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia
- PMID: 10350026
- DOI: 10.1097/00004714-199906000-00002
Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia
Abstract
Prevalence and risk factors for extrapyramidal syndromes (EPS) were investigated in a sample of 1,559 patients. The overall prevalence of EPS was 29.4% (N = 458). Among the EPS-diagnosed patients, parkinsonism as assessed by the presence of core parkinsonian symptoms (rigidity, tremor, bradykinesia) was present in 65.9% of patients (N = 302), akathisia in 31.8% (N = 145), and acute dystonia in 2.1% (N = 10). Old age and long-term neuroleptic drug (NL) treatment were significantly associated with EPS in both the univariate and the multivariate analyses, whereas no relationship was observed with average NL daily doses and current NL treatment. EPS was diagnosed in 50.2% of 285 patients with persistent tardive dyskinesia (TD). Distribution of EPS in patients with TD showed that tremor and akathisia were more frequent in peripheral TD cases than in orofacial TD cases. Furthermore, there was a stronger association of NL-induced parkinsonism with peripheral TD than with orofacial TD. This study suggests that the association between EPS and TD may be limited to specific subtypes of TD. Peripheral TD showed a higher association with parkinsonism and with akathisia, suggesting that these symptoms may share a common pathophysiology.
Similar articles
-
Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.Schizophr Res. 2008 Mar;100(1-3):97-107. doi: 10.1016/j.schres.2007.10.018. Epub 2007 Dec 11. Schizophr Res. 2008. PMID: 18055180
-
Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.Aust N Z J Psychiatry. 2004 Jun;38(6):445-9. doi: 10.1080/j.1440-1614.2004.01382.x. Aust N Z J Psychiatry. 2004. PMID: 15209837
-
Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S76-80. Can J Psychiatry. 1994. PMID: 7874668 Review.
-
The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curaçao Extrapyramidal Syndromes Study II.Schizophr Res. 1997 Aug 29;26(2-3):235-42. doi: 10.1016/s0920-9964(97)00058-3. Schizophr Res. 1997. PMID: 9323356
-
Tardive drug-induced extrapyramidal syndromes.Pharmacopsychiatry. 2000 Sep;33 Suppl 1:14-33. doi: 10.1055/s-2000-7672. Pharmacopsychiatry. 2000. PMID: 11072762 Review.
Cited by
-
Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?J Psychopharmacol. 2014 Jul;28(7):665-70. doi: 10.1177/0269881114523861. Epub 2014 Mar 4. J Psychopharmacol. 2014. PMID: 24595968 Free PMC article.
-
Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients.Biomedicines. 2021 Jul 23;9(8):879. doi: 10.3390/biomedicines9080879. Biomedicines. 2021. PMID: 34440083 Free PMC article. Review.
-
Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population.BMC Neurol. 2005 Mar 17;5(1):5. doi: 10.1186/1471-2377-5-5. BMC Neurol. 2005. PMID: 15774006 Free PMC article.
-
Risk factors, clinical correlates, and social functions of Chinese schizophrenia patients with drug-induced parkinsonism: A cross-sectional analysis of a multicenter, observational, real-world, prospective cohort study.Front Pharmacol. 2023 Mar 3;14:1077607. doi: 10.3389/fphar.2023.1077607. eCollection 2023. Front Pharmacol. 2023. PMID: 36937864 Free PMC article.
-
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Drug Saf. 2012 Oct 1;35(10):819-36. doi: 10.1007/BF03261978. Drug Saf. 2012. PMID: 22967188
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources